European thyroid journal · 2026
Prevalence and outcome of metastases to the thyroid gland: a nationwide database study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dombrée Monique S, Sloot Yvette, Hugen Niek, Voorham Quirinus J, van Engen-van Grunsven Ilse, Nagtegaal Iris D, Netea-Maier Romana T
Аннотация
OBJECTIVE: Metastases to the thyroid are seen relatively often in autopsy studies. In clinical studies, they are described as a rare occurrence. This study aimed to provide a more extensive representation of the origin, timing, and survival of patients diagnosed with thyroid metastases in the Netherlands.
METHODS: We performed a retrospective database study using two Dutch nationwide resources. In the Dutch Nationwide Pathology Databank (PALGA) database, we identified 575 patients between 1989 and 2014 with proven thyroid metastases. These patient records were linked with data from the Netherlands Cancer Registry (NCR) to assess whether the presence of these metastases had any impact on patients' survival. Complete survival data were available for 463 patients.
RESULTS: The most frequently diagnosed primary tumors were lung (29.4%), kidney (16.5%), and breast carcinoma (10.1%). However, thyroid metastases can originate from any primary tumor. The median time to diagnosis of thyroid metastasis was 17.2 months after the primary diagnosis. In 36 patients, the latency period was over 10 years. In 77% of patients, thyroid metastasis was part of pathologically proven widespread disease. Survival after diagnosis of thyroid metastasis was poor, with a median survival of 12.3 months.
CONCLUSION: Clinically relevant metastases to the thyroid are relatively rare and occur in a large variety of tumor types. Most of them occur in the context of advanced metastatic disease, and therefore, prognosis and indication for surgical treatment depend on the extent of the primary tumor, general health of the patient, and presence of local symptoms.
METHODS: We performed a retrospective database study using two Dutch nationwide resources. In the Dutch Nationwide Pathology Databank (PALGA) database, we identified 575 patients between 1989 and 2014 with proven thyroid metastases. These patient records were linked with data from the Netherlands Cancer Registry (NCR) to assess whether the presence of these metastases had any impact on patients' survival. Complete survival data were available for 463 patients.
RESULTS: The most frequently diagnosed primary tumors were lung (29.4%), kidney (16.5%), and breast carcinoma (10.1%). However, thyroid metastases can originate from any primary tumor. The median time to diagnosis of thyroid metastasis was 17.2 months after the primary diagnosis. In 36 patients, the latency period was over 10 years. In 77% of patients, thyroid metastasis was part of pathologically proven widespread disease. Survival after diagnosis of thyroid metastasis was poor, with a median survival of 12.3 months.
CONCLUSION: Clinically relevant metastases to the thyroid are relatively rare and occur in a large variety of tumor types. Most of them occur in the context of advanced metastatic disease, and therefore, prognosis and indication for surgical treatment depend on the extent of the primary tumor, general health of the patient, and presence of local symptoms.